title: Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome.
abstract: We conducted a retrospective analysis to investigate the natural history and the clinical outcome after treatment of primary gastric lymphoma of T-cell origin. Seventeen cases of T-cell origin among 444 primary gastric lymphoma patients were analyzed. The median age of the 14 male and 3 female patients was 49 years (range 22-76 years). The median progression-free survival (PFS) and overall survival (OS) were only 10 months (95% CI; 0-20 months), and 12 months (95% CI; 4-21 months), respectively. This study showed that the incidence of this subtype of T-cell gastric lymphoma was very rare, and had poor prognosis.
authors.affiliation: Department of Hematology-Oncology, Korea Institute of Radiological & Medical Sciences, Nowon-ku, Seoul, Republic of Korea. yhpark1229@yahoo.com
authors.forename: Yeon Hee
authors.initials: YH
authors.lastname: Park
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.forename: Soo Mee
authors.initials: SM
authors.lastname: Bang
authors.forename: Soon Il
authors.initials: SI
authors.lastname: Lee
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Kang
authors.forename: Im Il
authors.initials: II
authors.lastname: Na
authors.forename: Sung Hyun
authors.initials: SH
authors.lastname: Yang
authors.forename: Seung-Sook
authors.initials: SS
authors.lastname: Lee
authors.forename: Ji Eun
authors.initials: JE
authors.lastname: Uhm
authors.forename: Jung Mi
authors.initials: JM
authors.lastname: Kwon
authors.forename: Kihyun
authors.initials: K
authors.lastname: Kim
authors.forename: Chul Won
authors.initials: CW
authors.lastname: Jung
authors.forename: Keunchil
authors.initials: K
authors.lastname: Park
authors.forename: Young H
authors.initials: YH
authors.lastname: Ko
authors.forename: Baek-Yeol
authors.initials: BY
authors.lastname: Ryoo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone